Simplify Logo
Sanofi

Sanofi

Global pharma company; vaccines and R&D

Medical Science Liaison Rhino Gastroenterology Southwest

Full-TimeDeadline 11/23/26
$146.3k - $211.3k/yr
Mid
Bachelor's, Master's, PharmD, PhD, MD
Remote in USA+1 more

More locations: Cambridge, MA, USA

Hybrid

Must reside in the assigned territory; substantial national and international travel may be required.

About the job

Requirements
  • An advanced degree in a technical, scientific, or medical field such as a Doctor of Medicine, Doctor of Philosophy, or Doctor of Pharmacy is preferred, or a relevant life-science degree such as Registered Nurse or Master of Science with Rhinology and/or Gastroenterology specialty is required.
  • Residence in the assigned territory is required.
  • A valid driver's license, clean driving record, and ability to pass a complete background check are required.
  • The employee must safely drive a company car to daily meetings and appointments and comply with company policies and traffic laws.
  • A clear understanding of medical practice, clinical decision-making, and healthcare systems related to patient care is required.
  • The ability to interpret scientific data and translate it to educational and research needs is required.
  • Understanding of research study design and execution is required.
  • Knowledge of local pharmaceutical-industry regulations and codes of practice, especially for non-promotional activities, is required.
  • Knowledge of relevant healthcare systems, the evolving medical landscape, regulatory and payer environments, public health, and industry trends is required.
  • Proficiency with digital tools is required.
Responsibilities
  • Conduct timely, appropriate, and frequent scientific exchanges with external experts to support understanding of the scientific and medical value of company products.
  • Execute stakeholder engagement plans, gather data, and develop and share medical insights that inform medical messages, plans, and future research.
  • Monitor medical and scientific developments, assess research opportunities, and support evidence-generation plans.
  • Recognize, record, and share insights about the needs of patients, consumers, regulators, payers, and healthcare providers.
  • Maintain appropriate communication among Medical Affairs, Medical Information, and Commercial Operations stakeholders while complying with legal, regulatory, industry, and company requirements.
  • Ensure excellence in governance processes and operational risk management.
  • Engage external stakeholders in one-on-one and group medical and scientific information exchanges.
  • Establish and maintain peer relationships with Key Opinion Leaders and other stakeholder partners.
  • Share approved medical and scientific information and answer stakeholder questions within regulatory guidelines.
  • Engage stakeholders regarding healthcare policies and guidelines affecting clinical practice at local, state, regional, federal, and national levels.
  • Map, identify, profile, and prioritize stakeholders using defined systems.
  • Plan territory and individual stakeholder medical strategies and engagement plans using the Scientific Engagement Model.
  • Attend scientific congresses and symposia and establish a company Medical presence as directed.
  • Organize educational meetings and local scientific advisory boards when requested.
  • Support speaker training to provide continued scientific support in the field.
  • Respond to unsolicited requests for medical information related to supported products and disease areas.
  • Collect feedback and reactions from multiple data sources and stakeholders.
  • Record and report insights and information using approved mechanisms and tools.
  • Evaluate published studies and stakeholder interactions to develop insights that inform scientific messages, plans, strategy, systems, and product development.
  • Maintain awareness of emerging evidence in the disease area and use it to enhance stakeholder discussions.
  • Distribute relevant scientific and medical information and external insights to internal stakeholders.
  • Collaborate with Commercial Operations, Business Development, Regulatory, and other functions on diligence reviews, medical and safety evaluations, product positioning, lifecycle evidence planning, and compliance needs.
  • Contribute to materials for internal and external stakeholders in accordance with company and applicable federal and national policies.
  • Monitor disease epidemiology and support protocol development for surveillance, compliance, pharmacovigilance, and effectiveness studies.
  • Identify data-collection opportunities during stakeholder interactions and report them through approved processes.
  • Monitor clinical-trial activity within the territory and suggest clinical-trial sites when requested.
  • Respond to unsolicited investigator-sponsored-study requests and support submissions through internal processes.
  • Operate independently in complex regulatory environments, both in person and through digital channels.
  • Manage a base of approximately 50 stakeholders and maintain the stakeholder-engagement tracking database.
  • Cover Arizona, New Mexico, Utah, and Southern California.
  • Plan daily stakeholder interactions and discussion points in accordance with Medical Affairs strategy.
  • Execute the defined Key Opinion Leader territory strategy and develop territory engagement plans aligned with medical strategy.
Desired Qualifications
  • At least two years of experience in the pharmaceutical industry, as a Medical Science Liaison, or in relevant clinical practice.
  • Relevant immunology clinical experience in a gastroenterology clinical environment.
  • Exemplary communication and presentation skills.
  • Experience working on multidisciplinary teams and managing a significant volume of projects.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.